Paula Jane Busse

Paula Jane Busse

Auto-generated profile, based on publicly available information

Paula Jane Busse

Department of Medicine, Division of Clinical Immunology, Icahn School of Medicine at Mount Sinai School of Medicine, New York, NY

Research Focus & Metrics

Academic Career Length

25Years (2002-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 October 2010 in Journal of Allergy and Clinical Immunology
Verified
Journal Article
Closed access
PBPaula J. Busse
Paula J. Busse
SMSameer K. Mathur
Sameer K. Mathur

1 January 2014 in World Allergy Organization Journal
Verified
Journal Article
Open access
PDF file
AYAnahí Yáñez
Anahí Yáñez
SCSang-Hoen Cho
Sang-Hoen Cho
JSJoan B Soriano
Joan B Soriano
LRLanny J Rosenwasser
Lanny J Rosenwasser
GRGustavo J Rodrigo
Gustavo J Rodrigo
SHStephen T Holgate
Stephen T Holgate
In the past, asthma was considered mainly as a childhood disease. However, asthma is an important cause of morbidity and mortality in the elderly nowadays. In addition, the burden of asthma is more significant in the elderly than in their younger counterparts, particularly with regard to mortality, hospitalization, medical costs or health-related quality of life. Nevertheless, asthma in the elderly is still been underdiagnosed and undertreated. Therefore, it is an imperative task to recognize our current challenges and to set future directions. This project aims to review the current literature and identify unmet needs in the fields of research and practice for asthma in the elderly. This will enable us to find new research directions, propose new therapeutic strategies, and ultimately improve outcomes for elderly people with asthma. There are data to suggest that asthma in older adults is phenotypically different from young patients, with potential impact on the diagnosis, assessment and management in this population. The diagnosis of AIE in older populations relies on the same clinical findings and diagnostic tests used in younger populations, but the interpretation of the clinical data is more difficult. The challenge today is to encourage new research in AIE but to use the existing knowledge we have to make the diagnosis of AIE, educate the patient, develop a therapeutic approach to control the disease, and ultimately provide a better quality of life to our elderly patients.

20 July 2007 in Clinical & Experimental Allergy
Verified
Journal Article
Closed access
PDF file
PBPaula J. Busse
Paula J. Busse
TZTeng Fei Zhang
Teng Fei Zhang
KSKamal Srivastava
Kamal Srivastava
BSBrian Schofield
Brian Schofield
XLXiu‐Min Li
Xiu‐Min Li

1 December 2005 in Journal of Allergy and Clinical Immunology
Verified
Journal Article
Closed access
PBPaula J. Busse
Paula J. Busse
TZTeng Fei Zhang
Teng Fei Zhang
KSKamal Srivastava
Kamal Srivastava
BLBernard P. Lin
Bernard P. Lin
BSBrian Schofield
Brian Schofield
XLXiu-Min Li
Xiu-Min Li

1 June 2017 in Journal of Allergy and Clinical Immunology
Verified
Journal Article
Closed access
PBPaula J. Busse
Paula J. Busse
JBJanette M. Birmingham
Janette M. Birmingham
ACAgustin Calatroni
Agustin Calatroni
JMJoseph Manzi
Joseph Manzi
AGAnna Goryachokovsky
Anna Goryachokovsky
JWJuan P. Wisnivesky
Juan P. Wisnivesky

1 March 2022 in The Journal of Allergy and Clinical Immunology: In Practice
Verified
Journal Article
Open access
PBPaula Busse
Paula Busse
AKAllen Kaplan
Allen Kaplan
Hereditary angioedema (HAE) is a rare, chronic, genetic disease that presents with nonpruritic angioedema of the face, extremities, airway (can be life-threatening), genitourinary system, and abdomen. These symptoms can significantly impair daily activities. Hereditary angioedema is classified into HAE owing to a deficiency of functional C1INH (HAE-C1INH) or HAE with normal C1INH (HAE-nl-C1INH). Both type I and II HAE-C1INH result from inherited or spontaneous mutations in the SERPING1 gene, which encodes for C1INH. These mutations result in C1INH dysfunction, leading to uncontrolled plasma kallikrein activity with excessive bradykinin production. Bradykinin receptor activation leads to vasodilation, increased vascular permeability, and smooth muscle contractions, resulting in submucosal angioedema through fluid extravasation. Hereditary angioedema nl-C1INH is caused by either a known or unknown genetic mutation. The underlying mechanism of HAE-nl-C1INH is less well understood but is thought to be related to bradykinin signaling. Plasma kallikrein inhibitors have been developed to inhibit the kallikrein-kinin pathway to prevent (prophylactic) and treat on-demand (acute) HAE attacks. Several of these medications are delivered through subcutaneous or intravenous injection, although new and emerging therapies include oral formulations. This article provides a historical review and describes the evolving landscape of available kallikrein inhibitors to treat HAE-C1INH.